Clinical trial of oral ALS therapy SPG302 is enrolling in Australia

Clinical trial of oral ALS therapy SPG302 is enrolling in Australia

Spinogenix has launched a clinical trial in Australia to investigate its amyotrophic lateral sclerosis (ALS) treatment candidate SPG302 in patients and healthy volunteers. The first-in-human Phase 1 clinical trial (NCT05882695), which is recruiting up to 112 participants, is being conducted at the Nucleus Network Melbourne, Australia. Its…

Quebec, Ontario add Albrioza to public reimbursement list

Amylyx Pharmaceuticals Canada has entered into product listing agreements with Quebec and Ontario to publicly reimburse Albrioza (sodium phenylbutyrate and ursodoxicoltaurine), which was recently approved for amyotrophic lateral sclerosis (ALS). The oral therapy, which is marketed in the U.S. as Relyvrio, has been added to the…

We’ve developed a dark sense of humor living with ALS

When I took my son to the doctor for his sports physical, the nurse went through a checklist of health history questions. The exchange took an unexpected turn when she asked about my husband’s health. “Is Dad healthy?” “No. He has ALS.” The nurse glanced at her computer screen.